Use of Incretin-Related Medications Will Grow by 47 Percent
A new study found that the incretin-related medications will see the strongest growth among type 2 diabetes drugs over the next nine years....
Advertisement
DPP-IV inhibitors and GLP-1 drugs, two classes of drugs for treating type 2 diabetes will experience the biggest growth in market share of all classes of drugs for the condition, according to a new study.
The study found that DPP-IV inhibitors and GLP-1 analogues would experience the biggest growth in market share among all drug classes, with a combined market share that will increase from 20% in 2010 to 47% in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The report found that Merck & Co.'s Januvia (sitagliptin) dominates DPP-IV drugs and will consolidate its position, while GLP-1 analogues will have a strong position as well, with Novo Nordisk's Victoza (liraglutide) having the opportunity to edge up due to delays in the launch of Bydureon (exenatide), a once-weekly GLP-1 analogue made by Eli Lily & Co., Amylin Pharmaceuticals and Alkermes.
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2012 Diabetes In Control, Inc.. All rights reserved.
Entries (RSS News)
